Evidence map›Paper›PMID 41040794›Full record

ArticleCureus2025

Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting Databases.

Mugita Sato, Koichi Kageyama, Seiichiro Ito, Yoko Ino, Waranee Bunchuailua, Suang Rungpragayphan, Tomofumi Yamazaki, Kana Sugishita, Sineenart Krichanchai, Satoshi Nakao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mugita SatoLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.
Koichi KageyamaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.
Seiichiro ItoLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.
Yoko InoLaboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu, JPN.
Waranee BunchuailuaHealth Consumer Protection and Pharmacy Administration, Silpakorn University, Nakohon Pathom, THA.
Suang RungpragayphanBiomedicine and Health Informatics, Silpakorn University, Nakohon Pathom, THA.
Tomofumi YamazakiLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.
Kana SugishitaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.
Sineenart KrichanchaiHealth Consumer Protection and Pharmacy Administration, Silpakorn University, Nakohon Pathom, THA.
Satoshi NakaoLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.
Pornsak SriamornsakFaculty of Pharmacy, Silpakorn University, Nakohon Pathom, THA.
Hirofumi TakeuchiLaboratory of Advanced Pharmaceutical Process Engineering, Gifu Pharmaceutical University, Gifu, JPN.
Mitsuhiro NakamuraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnti-vascular endothelial growth factor (VEGF) agents are the first-line therapies for macular edema, diabetic macular edema, and exudative age-related macular degeneration secondary to retinal vein occlusion. Although adverse events, including cerebral infarction, are rare, their potential severity warrants further investigation. This study aimed to evaluate the risk and time to onset of adverse events, including cerebral infarction, associated with anti-VEGF agents using the Japanese Adverse Drug Event Report (JADER) database.

methodsAdverse events were coded using the Medical Dictionary for Regulatory Activities, and reporting odds ratios were calculated. The number of reports and median time to onset (interquartile range) were determined. Survival analyses were performed employing the log-rank test and the generalized Wilcoxon test.

resultsFrom April 2004 to January 2025, 965,286 reports were included in the JADER database. The number of adverse event reports for aflibercept (IVA), ranibizumab (IVR), brolucizumab (IVB), and faricimab (IVF) was 1,217, 1,223, 1,064, and 199, respectively. Furthermore, the reported numbers of cerebral infarction cases associated with IVA, IVR, IVB, and IVF were 200, 154, 16, and 20, respectively. The median (interquartile range) time to onset of cerebral infarction associated with IVA and IVR was 79.0 (range: 28.0-274.0) days and 48.5 (range: 14.0-142.5) days, respectively, with a significant difference in the time trend (log-rank test: p = 0.0100 and generalized Wilcoxon test: p = 0.0067).

conclusionThe findings suggest that cerebral infarction may develop earlier with IVR use than with IVA use and highlight the need for careful monitoring and individualized treatment strategies in clinical practice.

Indexed as

afliberceptage-related macular degenerationjapanese adverse drug event report databaseranibizumabtime-to-onset analysis

Identifiers

PMID41040794
PMCPMC12485568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.